CSL (OTCMKTS:CSLLY) Shares Gap Up – What’s Next?

Posted by Geri Gentry on Oct 9th, 2026

CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) shares gapped up prior to trading on Wednesday. The stock had previously closed at $30.92, but opened at $32.1430. CSL shares last traded at $31.30, with a volume of 906 shares traded.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CSLLY shares. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Royal Bank Of Canada upgraded shares of CSL from a “hold” rating to a “moderate buy” rating in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, CSL presently has a consensus rating of “Hold”.

Read Our Latest Report on CSL

CSL Stock Performance

The firm has a 50 day moving average of $29.22 and a 200-day moving average of $23.88. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.97 and a current ratio of 2.21.

CSL Company Profile

(Get Free Report)

CSL Limited is an Australia-based biopharmaceutical company that develops and manufactures medicines, vaccines and other healthcare products. The company serves patients, healthcare providers and public health systems worldwide through its major businesses, CSL Behring, CSL Seqirus and CSL Vifor.

CSL Behring specializes in plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders, hereditary angioedema and other rare or serious conditions. CSL Seqirus develops and supplies influenza vaccines and other vaccines, while CSL Vifor focuses on treatments for iron deficiency, kidney disease and related conditions.

The company traces its origins to Commonwealth Serum Laboratories, which was established by the Australian government in 1916.